Compile Data Set for Download or QSAR
Report error Found 280 with Last Name = 'appleman' and Initial = 'jr'
TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513956(US11059824, Compound loxoribine)
Affinity DataEC50:  3.22E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513957(US11059824, Compound 1)
Affinity DataEC50:  1.88E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513958(US11059824, Compound 2)
Affinity DataEC50:  2.98E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513959(US11059824, Compound 5)
Affinity DataEC50:  2.92E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513961(US11059824, Compound 6)
Affinity DataEC50:  8.35E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513962(US11059824, Compound 7)
Affinity DataEC50:  5.35E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513963(US11059824, Compound 8)
Affinity DataEC50:  4.13E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513964(US11059824, Compound 9)
Affinity DataEC50:  1.50E+4nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513965(US11059824, Compound 10)
Affinity DataEC50:  2.48E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513966(US11059824, Compound 11)
Affinity DataEC50:  2.49E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513968(US11059824, Compound 12)
Affinity DataEC50:  4.07E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513969(US11059824, Compound 13)
Affinity DataEC50:  1.51E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513970(US11059824, Compound 14)
Affinity DataEC50:  1.80E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513971(US11059824, Compound 15)
Affinity DataEC50: >5.00E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513972(US11059824, Compound 16)
Affinity DataEC50:  5.34E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513973(US11059824, Compound 17)
Affinity DataEC50:  3.37E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513974(US11059824, Compound 18)
Affinity DataEC50:  3.30E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513975(US11059824, Compound 19)
Affinity DataEC50:  4.91E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513976(US11059824, Compound 20)
Affinity DataEC50:  7.90E+4nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513977(US11059824, Compound 21)
Affinity DataEC50:  5.20E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513978(US11059824, Compound 22)
Affinity DataEC50:  5.67E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513981(US11059824, Compound 23)
Affinity DataEC50: >5.00E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513982(US11059824, Compound 26)
Affinity DataEC50:  5.19E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513983(US11059824, Compound 27)
Affinity DataEC50:  3.76E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513984(US11059824, Compound 28)
Affinity DataEC50:  4.70E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513985(US11059824, Compound 33)
Affinity DataEC50:  6.88E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513986(US11059824, Compound 34)
Affinity DataEC50:  5.12E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513987(US11059824, Compound 35)
Affinity DataEC50:  1.16E+6nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513988(US11059824, Compound 36)
Affinity DataEC50:  1.21E+6nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetToll-like receptor 7(Human)
Primmune Therapeutics

US Patent
LigandPNGBDBM513989(US11059824, Compound 37)
Affinity DataEC50:  5.64E+5nMAssay Description:The engagement of TLRs by cognate ligands triggers downstream signaling cascades, leading to the activation of NF-κB and other transcription fac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetEukaryotic initiation factor 4A-I(Human)
Inception Therapeutics

Curated by ChEMBL
LigandPNGBDBM50196926(Rocaglamide | CHEMBL438139 | US10085988, Compound ...)
Affinity DataKd:  156nMAssay Description:Binding affinity to full length recombinant eIF4A1 (unknown origin) assessed as induction ternary complex formation in presence of AGAGAG by measurin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetEukaryotic initiation factor 4A-I(Human)
Inception Therapeutics

Curated by ChEMBL
LigandPNGBDBM50540861(Zotatifin | Eft226 | EFT-226)
Affinity DataKd:  21nMAssay Description:Binding affinity to full length recombinant eIF4A1 (unknown origin) assessed as induction ternary complex formation in presence of AGAGAG by measurin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetEukaryotic initiation factor 4A-I(Human)
Inception Therapeutics

Curated by ChEMBL
LigandPNGBDBM50540861(Zotatifin | Eft226 | EFT-226)
Affinity DataKd:  3.19E+3nMAssay Description:Binding affinity to full length recombinant eIF4A1 (unknown origin) assessed as induction ternary complex formation in presence of AGAGAG by measurin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetEukaryotic initiation factor 4A-I(Human)
Inception Therapeutics

Curated by ChEMBL
LigandPNGBDBM50540861(Zotatifin | Eft226 | EFT-226)
Affinity DataKd:  9.60E+3nMAssay Description:Binding affinity to full length recombinant eIF4A1 (unknown origin) assessed as induction ternary complex formation in presence of AGAGAG by measurin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetEukaryotic initiation factor 4A-I(Human)
Inception Therapeutics

Curated by ChEMBL
LigandPNGBDBM50540861(Zotatifin | Eft226 | EFT-226)
Affinity DataKd:  2.43E+3nMAssay Description:Binding affinity to full length recombinant eIF4A1 (unknown origin) assessed as induction ternary complex formation in presence of AGAGAG by measurin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263270(CHEMBL4086747)
Affinity DataIC50: 0.0840nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263254(CHEMBL4094975)
Affinity DataIC50: 0.130nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263253(CHEMBL4067557)
Affinity DataIC50: 0.140nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM168214(US9669031, 207 6′-((6-aminopyrimidin-4-yl)am...)
Affinity DataIC50: 0.310nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263270(CHEMBL4086747)
Affinity DataIC50: 0.360nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM168214(US9669031, 207 6′-((6-aminopyrimidin-4-yl)am...)
Affinity DataIC50: 0.510nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263254(CHEMBL4094975)
Affinity DataIC50: 0.620nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263269(CHEMBL4076439)
Affinity DataIC50: 0.650nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263269(CHEMBL4076439)
Affinity DataIC50: 0.680nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1/2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263269(CHEMBL4076439)
Affinity DataIC50: 0.790nMAssay Description:Inhibition of MNK1/2 in human HCT116 cells assessed as decrease in eIF4E phosphorylation at Ser209 after 2 hrs by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263254(CHEMBL4094975)
Affinity DataIC50: 0.880nMAssay Description:Inhibition of full length GST-tagged recombinant human MNK1 expressed in insect cells using Ac-TATKSGSTTKNR-NH2 as substrate preincubated for 5 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263255(CHEMBL4065802)
Affinity DataIC50: 1nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM50263263(CHEMBL4073443)
Affinity DataIC50: 1nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM168216(US9669031, 79 3,3-dimethyl-6-(pyrimidin-4-ylamino)...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Effector Therapeutics

Curated by ChEMBL
LigandPNGBDBM168222(US9669031, 93 6-[(6-aminopyrimidin-4-yl)amino]-8-c...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of full length N-terminal GST-tagged recombinant human MNK2 expressed in baculovirus expression system using Ac-TATKSGSTTKNR-NH2 as substr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/29/2020
Entry Details Article
PubMed
Displayed 1 to 50 (of 280 total ) | Next | Last >>
Jump to: